Goodwin advised Blueprint Medicines on the deal
Blueprint Medicines (NASDAQ: BPMC), on its underwritten public offering of 4,662,162 shares of its common stock at a public offering price of $74.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $327.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Guggenheim Securities, LLC and Wedbush Securities Inc. acted as co-lead managers for the offering.
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, Blueprint is developing transformational medicines rooted in its leading expertise in protein kinases, which are proven drivers of disease.
The Goodwin team was led by partners Danielle Lauzon (Picture) and Kingsley Taft, and included associates Yasin Akbari, Kaitlin Adams, and Patricia Mets, and counsel Stephanie Philbin.
Law Firms: Goodwin Procter;
Clients: Blueprint Medicines;